SSTR PET: Imaging Neuroendocrine Tumors
February 1, 2023
Country of Publication
The goal of providing guidelines is to assist physicians in recommending, performing, interpreting and reporting the results of SSTR PET imaging studies for patients with NETs. This document aims to provide clinicians with the best available evidence, to inform where robust evidence is lacking, and to help them to deliver the best possible diagnostic efficacy and study quality for their patients. This guideline also presents standardized quality control/quality assurance (QC/QA) procedures and imaging procedures for SSTR PET. Adequate precision, accuracy, repeatability, and reproducibility are essential for the clinical management of patients and the use of SSTR PET within multicenter trials. A standardized imaging procedure will help to promote the appropriate use of SSTR PET and enhance subsequent research.
Male, Female, Adult, Older adult
Health Care Settings
Outpatient, Radiology services
Nurse, nurse practitioner, physician, physician assistant
Diagnosis, Assessment and screening
D018278 - Carcinoma, Neuroendocrine, D049268 - Positron-Emission Tomography, D013004 - Somatostatin
positron emission tomography (PET), Neuroendocrine tumor, SSTR, Somatostatin receptor, PET, positron emission tomography, NETs
Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860. PMID: 36725249.